Company to view next
Generic selectors
Exact matches only
Search in title
Search in content

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company’s lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

12

Address:

AzurRx BioPharma, Inc. 1615 South Congress Avenue Suite 103 Delray Beach FL 33445 United States

Website:

http://www.azurrx.com

Phone:

646-699-7855

Leave a comment

Your email address will not be published. Required fields are marked *